Skip to main content
Evidence Snapshot

Nischarin

CHEMBL3923 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T05:13:45Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3923
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Nischarin as ChEMBL target CHEMBL3923, mapped to UniProt Q9Y2I1. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Nischarin
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3923
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9Y2I1
Nischarin
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Nischarin matters

As of 2026-09-13

Nischarin is reviewed as Nischarin (UniProt Q9Y2I1); Nischarin shows approved-linked disease relevance led by hypertension. 2 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 10 approved drugs, 202 compounds, and 38 assays, with lead potency reaching pChEMBL 9.7.

Disease context
hypertension

Nischarin shows approved-linked disease relevance led by hypertension. 2 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 2 additional disease programs remain visible in the same card. Linked drugs include MOXONIDINE, RILMENIDINE.

Start review with hypertension because it currently carries approved-linked support. Linked drugs include MOXONIDINE, RILMENIDINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 10 approved drugs, 202 compounds, and 38 assays for this target. The dominant activity type is KI. CHEMBL3546401 is the current potency anchor at pChEMBL 9.7.

Use CHEMBL3546401 as the tractability anchor when discussing potency (pChEMBL 9.7).

Activity source · ChEMBL 36 via Core Engine
10 approved pChEMBL 9.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Nischarin matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9Y2I1, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why hypertension is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

202
Total Compounds
38
Total Assays
10
Approved Drugs
IC50: 19.0, KI: 277.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3546401
 9.7 Ki —
No preferred name
CHEMBL266155
 9.2 Ki —
No preferred name
CHEMBL14097
 9.1 Ki —
No preferred name
CHEMBL14640
 9.0 Ki —
No preferred name
CHEMBL2092861
 9.0 Ki —

Approved Drugs

Structure Compound First Approval
TIZANIDINE
CHEMBL1079
 1996
MOXONIDINE
CHEMBL19236
 1991
RILMENIDINE
CHEMBL289480
 1987
OXYMETAZOLINE
CHEMBL762
 1986
GUANFACINE
CHEMBL862
 1986
GUANABENZ
CHEMBL420
 1982
CLONIDINE
CHEMBL134
 1974
NAPHAZOLINE
CHEMBL761
 1971
PHENTOLAMINE
CHEMBL597
 1952
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T05:13:45Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3923